{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:42:18Z","timestamp":1785307338430,"version":"3.55.0"},"reference-count":139,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010798","name":"Sunway University","doi-asserted-by":"publisher","award":["INT-2019-SST-CVVR-01"],"award-info":[{"award-number":["INT-2019-SST-CVVR-01"]}],"id":[{"id":"10.13039\/501100010798","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Dengue virus (DENV) presents a significant threat to global public health with more than 500,000 hospitalizations and 25,000 deaths annually. Currently, there is no clinically approved antiviral drug to treat DENV infection. The envelope (E) glycoprotein of DENV is a promising target for drug discovery as the E protein is important for viral attachment and fusion. Understanding the structure and function of DENV E protein has led to the exploration of structure-based drug discovery of antiviral compounds and peptides against DENV infections. This review summarizes the structural information of the DENV E protein with regards to DENV attachment and fusion. The information enables the development of antiviral agents through structure-based approaches. In addition, this review compares the potency of antivirals targeting the E protein with the antivirals targeting DENV multifunctional enzymes, repurposed drugs and clinically approved antiviral drugs. None of the current DENV antiviral candidates possess potency similar to the approved antiviral drugs which indicates that more efforts and resources must be invested before an effective DENV drug materializes.<\/jats:p>","DOI":"10.3390\/v12040367","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T10:29:38Z","timestamp":1585650578000},"page":"367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus"],"prefix":"10.3390","volume":"12","author":[{"given":"Mohd Ishtiaq","family":"Anasir","sequence":"first","affiliation":[{"name":"Center for Virus and Vaccine Research, School of Science and Technology, Sunway University, Kuala Lumpur, Selangor 47500, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3916","authenticated-orcid":false,"given":"Babu","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, School of Science and Technology, Sunway University, Kuala Lumpur, Selangor 47500, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-6291","authenticated-orcid":false,"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[{"name":"Center for Virus and Vaccine Research, School of Science and Technology, Sunway University, Kuala Lumpur, Selangor 47500, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1473-3099(16)30167-0","article-title":"SAGE committee advice on dengue vaccine","volume":"16","author":"Pang","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: Development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e019368","DOI":"10.1136\/bmjopen-2017-019368","article-title":"Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2\u201317 years: Systematic review and meta-analysis","volume":"9","author":"Rosa","year":"2019","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.antiviral.2013.09.013","article-title":"Ten years of dengue drug discovery: Progress and prospects","volume":"100","author":"Lim","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","article-title":"Dengue infection","volume":"2","author":"Guzman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/jvi.69.11.7232-7243.1995","article-title":"Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum","volume":"69","author":"Falgout","year":"1995","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-virology-110615-042334","article-title":"Properties and functions of the Dengue virus capsid protein","volume":"3","author":"Byk","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, X., Jia, R., Shen, H., Wang, M., Yin, Z., and Cheng, A. (2017). Structures and functions of the envelope glycoprotein in flavivirus infections. Viruses, 9.","DOI":"10.3390\/v9110338"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rosales Ramirez, R., and Ludert, J.E. (2019). The dengue virus nonstructural protein 1 (NS1) is secreted from mosquito cells in association with the intracellular cholesterol transporter chaperone caveolin complex. J. Virol., 93.","DOI":"10.1128\/JVI.01985-18"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bcp.2018.04.008","article-title":"Dengue virus NS2 and NS4: Minor proteins, mammoth roles","volume":"154","author":"Chin","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1038\/s41598-019-39157-7","article-title":"Dengue virus nonstructural 3 protein interacts directly with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reduces its glycolytic activity","volume":"9","author":"Silva","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"El Sahili, A., and Lescar, J. (2017). Dengue virus non-structural protein 5. Viruses, 9.","DOI":"10.3390\/v9040091"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2015.03.014","article-title":"The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development","volume":"118","author":"Luo","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.01429-12","article-title":"A novel inhibitor of dengue virus replication that targets the capsid protein","volume":"57","author":"Byrd","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21992","DOI":"10.1074\/jbc.M111.332643","article-title":"Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases","volume":"287","author":"Becker","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2013.05.011","article-title":"Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication","volume":"99","author":"Overheul","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0966-842X(01)02288-0","article-title":"Epidemic dengue\/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century","volume":"10","author":"Gubler","year":"2002","journal-title":"Trends Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/IDR.S22613","article-title":"Treatment of dengue fever","volume":"5","author":"Rajapakse","year":"2012","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1086\/528805","article-title":"Dengue and dengue hemorrhagic fever among adults: Clinical outcomes related to viremia, serotypes, and antibody response","volume":"197","author":"Guilarde","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/343813","article-title":"High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever","volume":"186","author":"Libraty","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hamel, R., Surasombatpattana, P., Wichit, S., Dauv\u00e9, A., Donato, C., Pompon, J., Vijaykrishna, D., Liegeois, F., Vargas, R.M., and Luplertlop, N. (2019). Phylogenetic analysis revealed the co-circulation of four dengue virus serotypes in Southern Thailand. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221179"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Shrivastava, S., Tiraki, D., Diwan, A., Lalwani, S.K., Modak, M., Mishra, A.C., and Arankalle, V.A. (2018). Co-circulation of all the four dengue virus serotypes and detection of a novel clade of DENV-4 (genotype I) virus in Pune, India during 2016 season. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192672"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tricou, V., Minh, N.N., Van, T.P., Lee, S.J., Farrar, J., Wills, B., Tran, H.T., and Simmons, C.P. (2010). A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000785"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/cis655","article-title":"Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: A randomized, placebo-controlled trial","volume":"55","author":"Tam","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","first-page":"468","article-title":"Lovastatin for the treatment of adult patients with dengue: A randomized, double-blind, placebo-controlled trial","volume":"62","author":"Whitehorn","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(14)70730-3","article-title":"Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): A phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"14","author":"Low","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.embor.embor866","article-title":"Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses","volume":"4","author":"Altmeyer","year":"2003","journal-title":"EMBO Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"282734","DOI":"10.1155\/2013\/282734","article-title":"Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6\/36 cells","volume":"2013","author":"Farias","year":"2013","journal-title":"Sci. World J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/1348-0421.12154","article-title":"Chloroquine interferes with dengue-2 virus replication in U937 cells","volume":"58","author":"Farias","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0074-02762013000500010","article-title":"Chloroquine use improves dengue-related symptoms","volume":"108","author":"Borges","year":"2013","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/vim.2014.0090","article-title":"Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys","volume":"28","author":"Farias","year":"2015","journal-title":"Viral Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H., Nguyen, T.H., Vu, T.T., Farrar, J., Hoang, T.L., Dong, T.H., Ngoc Tran, V., Phung, K.L., Wolbers, M., and Whitehead, S.S. (2013). Corticosteroids for dengue\u2014Why don\u2019t they work?. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002592"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2009.03.025","article-title":"Cholesterol biosynthesis modulation regulates dengue viral replication","volume":"389","author":"Rothwell","year":"2009","journal-title":"Virology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1745-6215-13-203","article-title":"Lovastatin for adult patients with dengue: Protocol for a randomised controlled trial","volume":"13","author":"Whitehorn","year":"2012","journal-title":"Trials"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000321892","article-title":"Statins reduce dengue virus production via decreased virion assembly","volume":"54","author":"Castellanos","year":"2011","journal-title":"Intervirology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Martinez-Gutierrez, M., Correa-Londo\u00f1o, L.A., Castellanos, J.E., Gallego-G\u00f3mez, J.C., and Osorio, J.E. (2014). Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087412"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3892\/mmr.2016.5519","article-title":"The anti-dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression","volume":"14","author":"Vidaltamayo","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17147","DOI":"10.1038\/s41598-018-35334-2","article-title":"Hyperlipidemia, statin use and dengue severity","volume":"8","author":"Chia","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14138","DOI":"10.1073\/pnas.0906467106","article-title":"Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection","volume":"106","author":"Souza","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Morrison, J., Rathore, A.P.S., Mantri, C.K., Aman, S.A.B., Nishida, A., and St John, A.L. (2017). Transcriptional profiling confirms the therapeutic effects of mast cell stabilization in a dengue disease model. J. Virol., 91.","DOI":"10.1128\/JVI.00617-17"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Tan, J.W., Wan Zahidi, N.F., Kow, A.S.F., Soo, K.M., Shaari, K., Israf, D.A., Chee, H.Y., and Tham, C.L. (2019). Mast cell stabilizing effect of a geranyl acetophenone in dengue virus infection using in vitro model of DENV3-induced RBL-2H3 cells. Biosci. Rep., 39.","DOI":"10.1042\/BSR20181273"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JVI.02841-13","article-title":"Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir","volume":"88","author":"Chen","year":"2014","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/13543784.2016.1201063","article-title":"Investigational drugs in early development for treating dengue infection","volume":"25","author":"Beesetti","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2010.11.002","article-title":"Combination of \u03b1-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo","volume":"89","author":"Chang","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1128\/AAC.04779-14","article-title":"Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors","volume":"59","author":"Yeo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/viro.2002.1685","article-title":"Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA","volume":"304","author":"Diamond","year":"2002","journal-title":"Virology"},{"key":"ref_52","first-page":"860","article-title":"Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection","volume":"10","author":"Durantel","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.antiviral.2011.10.002","article-title":"Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model","volume":"92","author":"Rathore","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sung, C., Wei, Y., Watanabe, S., Lee, H.S., Khoo, Y.M., Fan, L., Rathore, A.P.S., Chan, K.W.-K., Choy, M.M., and Kamaraj, U.S. (2016). Extended evaluation of virological, immunological and pharmacokinetic endpoints of CELADEN: A randomized, placebo-controlled trial of celgosivir in dengue fever patients. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004851"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.12.008","article-title":"Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy","volume":"127","author":"Watanabe","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","article-title":"Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4","volume":"129","author":"Warfield","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.antiviral.2013.01.004","article-title":"An iminosugar with potent inhibition of dengue virus infection in vivo","volume":"98","author":"Perry","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1128\/JVI.00028-15","article-title":"Dengue virus evolution under a host-targeted antiviral","volume":"89","author":"Plummer","year":"2015","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_60","unstructured":"Avirutnam, P. (2016, January 9\u201312). Ivermectin: A promising anti-dengue replication treatment [abstract S634]. Proceedings of the 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Xu, T.-L., Han, Y., Liu, W., Pang, X.-Y., Zheng, B., Zhang, Y., and Zhou, X.-N. (2018). Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006934"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00816","DOI":"10.1016\/j.heliyon.2018.e00816","article-title":"Effectiveness of corticosteroid in the treatment of dengue\u2014A systemic review","volume":"4","author":"Bandara","year":"2018","journal-title":"Heliyon"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/j.ijid.2011.03.006","article-title":"Effect of a single dose of methyl prednisolone as rescue medication for patients who develop hypotensive dengue shock syndrome during the febrile phase: A retrospective observational study","volume":"15","author":"Premaratna","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"ref_64","first-page":"567","article-title":"The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation","volume":"3","author":"Gelosa","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","article-title":"Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C","volume":"48","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Ann. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine involves a second metabolic pathway leading to beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Han, B., Parhy, B., Zhou, E., Hsieh, D., Camus, G., Martin, R., Svarovskaia, E.S., Mo, H., and Dvory-Sobol, H. (2019). In vitro susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pangenotypic NS3\/4A inhibitor voxilaprevir. J. Clin. Microbiol., 57.","DOI":"10.1128\/JCM.01844-18"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ng, T.I., Tripathi, R., Reisch, T., Lu, L., Middleton, T., Hopkins, T.A., Pithawalla, R., Irvin, M., Dekhtyar, T., and Krishnan, P. (2017). In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01620-17"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","article-title":"Evaluation of sofosbuvir (\u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine) as an inhibitor of dengue virus replication","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1021\/ml500245v","article-title":"C-terminal residue optimization and fragment merging: Discovery of a potent Peptide-hybrid inhibitor of dengue protease","volume":"5","author":"Behnam","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1021\/acs.jmedchem.5b00612","article-title":"Phenylalanine and phenylglycine analogues as arginine mimetics in dengue protease inhibitors","volume":"58","author":"Weigel","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bbrc.2013.09.078","article-title":"A small compound targeting the interaction between nonstructural proteins 2B and 3 inhibits dengue virus replication","volume":"440","author":"Pambudi","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hariono, M., Choi, S.B., Roslim, R.F., Nawi, M.S., Tan, M.L., Kamarulzaman, E.E., Mohamed, N., Yusof, R., Othman, S., and Abd Rahman, N. (2019). Thioguanine-based DENV-2 NS2B\/NS3 protease inhibitors: Virtual screening, synthesis, biological evaluation and molecular modelling. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210869"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1128\/AAC.02251-12","article-title":"Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase","volume":"57","author":"Byrd","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1128\/JVI.02451-09","article-title":"Inhibition of dengue virus polymerase by blocking of the RNA tunnel","volume":"84","author":"Niyomrattanakit","year":"2010","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1128\/JVI.00855-15","article-title":"Discovery of dengue virus NS4B inhibitors","volume":"89","author":"Wang","year":"2015","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11540","DOI":"10.1128\/JVI.01745-14","article-title":"Characterization of the mode of action of a potent dengue virus capsid inhibitor","volume":"88","author":"Scaturro","year":"2014","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Yin","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1128\/JVI.05468-11","article-title":"Inhibition of dengue virus by targeting viral NS4B protein","volume":"85","author":"Xie","year":"2011","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/978-1-4614-7651-1_8","article-title":"Class II fusion proteins","volume":"790","author":"Modis","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1073\/pnas.0832193100","article-title":"A ligand-binding pocket in the dengue virus envelope glycoprotein","volume":"100","author":"Modis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(02)00660-8","article-title":"Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion","volume":"108","author":"Kuhn","year":"2002","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmb.2009.07.035","article-title":"Interaction of the Dengue virus fusion peptide with membranes assessed by NMR: The essential role of the envelope protein Trp101 for membrane fusion","volume":"392","author":"Melo","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature02165","article-title":"Structure of the dengue virus envelope protein after membrane fusion","volume":"427","author":"Modis","year":"2004","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.str.2004.06.019","article-title":"Conformational changes of the flavivirus E glycoprotein","volume":"12","author":"Zhang","year":"2004","journal-title":"Structure"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/JVI.02458-10","article-title":"The unique transmembrane hairpin of flavivirus fusion protein E is essential for membrane fusion","volume":"85","author":"Fritz","year":"2011","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/v5020605","article-title":"Carbohydrate-related inhibitors of dengue virus entry","volume":"5","author":"Hidari","year":"2013","journal-title":"Viruses"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1128\/JVI.02957-12","article-title":"Structure of a dengue virus envelope protein late-stage fusion intermediate","volume":"87","author":"Klein","year":"2013","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virol.2013.03.011","article-title":"Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion","volume":"441","author":"Roehrig","year":"2013","journal-title":"Virology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2007.05.042","article-title":"Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus","volume":"366","author":"Gromowski","year":"2007","journal-title":"Virology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/viro.1998.9200","article-title":"Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica","volume":"246","author":"Roehrig","year":"1998","journal-title":"Virology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1128\/JVI.00432-07","article-title":"Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes","volume":"81","author":"Austin","year":"2007","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1099\/0022-1317-82-8-1885","article-title":"Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: Insight into the neutralization mechanism","volume":"82","author":"Thullier","year":"2001","journal-title":"J. Gen. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/JVI.06871-11","article-title":"Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera","volume":"86","author":"Wahala","year":"2012","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2018.04.018","article-title":"Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with beta3 integrin","volume":"155","author":"Cui","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2005.11.042","article-title":"Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN","volume":"124","author":"Pokidysheva","year":"2006","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1128\/JVI.79.2.1223-1231.2005","article-title":"Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein","volume":"79","author":"Modis","year":"2005","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Stiasny, K., K\u00f6ssl, C., Lepault, J., Rey, F.A., and Heinz, F.X. (2007). Characterization of a structural intermediate of flavivirus membrane fusion. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030020"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1128\/JVI.00170-10","article-title":"In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein","volume":"84","author":"Liao","year":"2010","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1099\/vir.0.19062-0","article-title":"The membrane proteins of flaviviruses form ion-permeable pores in the target membrane after fusion: Identification of the pores and analysis of their possible role in virus infection","volume":"84","author":"Koschinski","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.chembiol.2018.05.011","article-title":"Inhibition of flaviviruses by targeting a conserved pocket on the viral envelope protein","volume":"25","author":"Lian","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/molecules16010221","article-title":"Targeting cell entry of enveloped viruses as an antiviral strategy","volume":"16","author":"Teissier","year":"2010","journal-title":"Molecules"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2040206618758524","DOI":"10.1177\/2040206618758524","article-title":"Addressing the selectivity and toxicity of antiviral nucleosides","volume":"26","author":"Feng","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yang, J.M., Chen, Y.F., Tu, Y.Y., Yen, K.R., and Yang, Y.L. (2007). Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000428"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/cb800176t","article-title":"Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein","volume":"3","author":"Zhou","year":"2008","journal-title":"ACS Chem. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.antiviral.2009.09.011","article-title":"A small molecule fusion inhibitor of dengue virus","volume":"84","author":"Poh","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.antiviral.2009.09.007","article-title":"In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses","volume":"84","author":"Kampmann","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10822-009-9263-6","article-title":"Identification of novel target sites and an inhibitor of the dengue virus E protein","volume":"23","author":"Yennamalli","year":"2009","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/AAC.01148-08","article-title":"A small-molecule dengue virus entry inhibitor","volume":"53","author":"Wang","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1021\/jm070683u","article-title":"From docking false-positive to active anti-HIV agent","volume":"50","author":"Barreiro","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"111628","DOI":"10.1016\/j.ejmech.2019.111628","article-title":"De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus","volume":"182","author":"Leal","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Batool, M., Ahmad, B., and Choi, S. (2019). A structure-based drug discovery paradigm. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112783"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1021\/acs.jmedchem.7b00487","article-title":"In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): Utility and best practices. An industry perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development","volume":"60","author":"Lombardo","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/minf.201501017","article-title":"Mind the gap! A journey towards computational toxicology","volume":"35","author":"Mangiatordi","year":"2016","journal-title":"Mol. Inform."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1021\/jm049756p","article-title":"Soft docking and multiple receptor conformations in virtual screening","volume":"47","author":"Ferrari","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/prot.22146","article-title":"Madamm: A multistaged docking with an automated molecular modeling protocol","volume":"74","author":"Cerqueira","year":"2009","journal-title":"Proteins"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cbdd.12309","article-title":"Peptide inhibitors against dengue virus infection","volume":"84","author":"Panya","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"719","DOI":"10.7150\/ijms.5037","article-title":"Inhibition of dengue virus entry into target cells using synthetic antiviral peptides","volume":"10","author":"Alhoot","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10867-018-9515-6","article-title":"Dynamics and binding interactions of peptide inhibitors of dengue virus entry","volume":"45","author":"Isa","year":"2019","journal-title":"J. Biol. Phys."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Costin, J.M., Jenwitheesuk, E., Lok, S.M., Hunsperger, E., Conrads, K.A., Fontaine, K.A., Rees, C.R., Rossmann, M.G., Isern, S., and Samudrala, R. (2010). Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000721"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1743-422X-2-49","article-title":"Peptide inhibitors of dengue virus and West Nile virus infectivity","volume":"2","author":"Hrobowski","year":"2005","journal-title":"Virol. J."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Lok, S.M., Costin, J.M., Hrobowski, Y.M., Hoffmann, A.R., Rowe, D.K., Kukkaro, P., Holdaway, H., Chipman, P., Fontaine, K.A., and Holbrook, M.R. (2012). Release of dengue virus genome induced by a peptide inhibitor. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050995"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Schmidt, A.G., Yang, P.L., and Harrison, S.C. (2010). Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000851"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"14339","DOI":"10.1038\/ncomms14339","article-title":"Conformational changes in intact dengue virus reveal serotype-specific expansion","volume":"8","author":"Lim","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1073\/pnas.1304300110","article-title":"Dengue structure differs at the temperatures of its human and mosquito hosts","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37 \u00b0C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J. Virol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1128\/JVI.01440-10","article-title":"Peptide inhibitors of flavivirus entry derived from the E protein stem","volume":"84","author":"Schmidt","year":"2010","journal-title":"J. Virol."},{"key":"ref_134","first-page":"223","article-title":"Scoring functions for ab initio protein structure prediction","volume":"143","author":"Huang","year":"2000","journal-title":"Methods Mol. Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"9837","DOI":"10.1128\/JVI.00736-06","article-title":"Inhibition of hendra virus fusion","volume":"80","author":"Porotto","year":"2006","journal-title":"J. Virol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Pessi, A., Langella, A., Capito, E., Ghezzi, S., Vicenzi, E., Poli, G., Ketas, T., Mathieu, C., Cortese, R., and Horvat, B. (2012). A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036833"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12977-019-0489-7","article-title":"Characterization of resistance to a potent D-peptide HIV entry inhibitor","volume":"16","author":"Smith","year":"2019","journal-title":"Retrovirology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:11:58Z","timestamp":1760173918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":139,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["v12040367"],"URL":"https:\/\/doi.org\/10.3390\/v12040367","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]}}}